ArticleCancer causes & control : CCC2026
Racial and ethnic disparities in receipt of guideline-concordant treatment for early-stage non-small cell lung cancer.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeNon-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in California, with Non-Hispanic Black (NHB) patients experiencing the highest mortality rates. Disparities in receipt of guideline-concordant treatment (GCT) contribute to these outcomes. This population-based study analyzed racial and ethnic differences in GCT receipt among early-stage NSCLC patients.
methodsPatients diagnosed with early-stage NSCLC (tumors ≤ 4 cm, no lymph node involvement, and no distant metastases) between 2012 and 2022 were identified from the Los Angeles County Cancer Surveillance Program. Logistic regression evaluated associations between race/ethnicity and receipt of GCT (surgery or radiation only vs. no treatment or multiple treatments), adjusting for potential confounders.
resultsIn our sample (n = 2,857), the average age was 69.6 years, 63.2% were female, mean tumor size was 1.9 cm, and the cohort was 57.3% Non-Hispanic White (NHW), 8.9% NHB, 14.2% Hispanic, and 18.8% Asian/Pacific Islander (API). While most patients (87.4%) received GCT, NHB and Hispanic patients had higher rates of non-GCT treatment (18.0% and 15.8%, respectively; p < 0.001). NHB patients had significantly higher odds of not receiving GCT compared with NHW patients (OR: 1.55, 95% CI: 1.07-2.26; p < 0.05). No significant differences were observed for API or Hispanic patients.
conclusionAddressing disparities in GCT for patients diagnosed with early-stage NSCLC is critical to improving survival outcomes. Future studies identifying factors influencing a patient's and physician's decision to receive, recommend, and adhere to GCT guidelines are needed to understand the complexity of treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.